Announcement
19 Dec 2025
In December 2025, the United States government announced an agreement with GSK to implement most-favoured-nation drug pricing for American patients.
Source
Sign in to access
Number of interventions
4
0 certainly harmful
4 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 05 Apr 2026
Local operations incentive
Recent update from 05 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 05 Apr 2026
FDI: Financial incentive
Recent update from 05 Apr 2026:
On 19 December 2025, the U.S. Administration announced an agreement with GSK. Under the agreement, GSK committed to make investments in R&D and manufacturing in the United States. In return, GS...
Sign in to see more
Updated: 05 Apr 2026
Tax or social insurance relief
Recent update from 05 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 05 Apr 2026
Import tariff
Recent update from 05 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.